Literature DB >> 11418364

The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241.

D Howe1, C Lynas.   

Abstract

BACKGROUND AND OBJECTIVES: The cyclin D1 gene, CCND1, is alternatively spliced to produce transcripts [a] and [b] in a manner apparently modulated by a polymorphism (A/G) at codon 241. Studies have indicated that the polymorphism can affect the prognosis of patients with different types of solid tumors. This study aimed to determine the relative levels of transcripts [a] and [b] in normal and malignant peripheral blood mononuclear cells (PBMNC), and to investigate whether these were influenced by the polymorphism. The impact of the polymorphism on the survival of a group of mantle cell lymphoma (MCL) patients was also to be studied. DESIGN AND METHODS: The polymorphism was genotyped, using restriction fragment length polymorphism analysis, in 74 patients (42 MCL, 19 chronic lymphocytic leukemia, 13 normal controls) and the relative level of transcripts [a] and [b] determined using a competitive reverse transcription polymerase chain reaction method. Kaplan-Meier survival curves and the log-rank test were used to analyze the survival data.
RESULTS: Of the cases genotyped, 39 were heterozygous for the polymorphism, 24 homozygous G and 11 homozygous A. Both transcripts [a] and [b] were expressed in normal PBMNC and malignant lymphocytes, with the polymorphism affecting their relative levels. Neither the predominant transcript, nor genotype, significantly influenced survival of the MCL patients studied. INTERPRETATION AND
CONCLUSIONS: Contrary to previous reports, patients who were homozygous A at the polymorphism produced more transcript [a] whilst homozygous G patients had more transcript [b]. In the small cohort studied, the polymorphism did not appear to affect the prognosis of the patients with MCL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418364

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.

Authors:  Andrew D Johnson; Ying Zhang; Audrey C Papp; Julia K Pinsonneault; Jeong-Eun Lim; David Saffen; Zunyan Dai; Danxin Wang; Wolfgang Sadée
Journal:  Pharmacogenet Genomics       Date:  2008-09       Impact factor: 2.089

3.  Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis.

Authors:  Zahra Soleimani; Davood Kheirkhah; Mohammad Reza Sharif; Alireza Sharif; Mohammad Karimian; Younes Aftabi
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

4.  Cyclin D1 splice variant and risk for non-Hodgkin lymphoma.

Authors:  Sophia S Wang; Wendy Cozen; Richard K Severson; Patricia Hartge; James R Cerhan; Scott Davis; Robert Welch; Nathaniel Rothman; Stephen J Chanock
Journal:  Hum Genet       Date:  2006-06-17       Impact factor: 4.132

5.  Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity.

Authors:  Chul Jang Kim; Yukihiro Tambe; Ken-Ichi Mukaisho; Hiroyuki Sugihara; Akihiro Kawauchi; Hirokazu Inoue
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

6.  Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Authors:  Vanita K Gupta; Andrew Feber; Liqiang Xi; Arjun Pennathur; Maoxin Wu; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

7.  Identification of variants in cyclin D1 ( CCND1) and B-Cell CLL/lymphoma 2 ( BCL2).

Authors:  Byung Lae Park; Lyoung Hyo Kim; Hyun Sub Cheong; Hye Young Cho; Eun Mi Kim; Hyoung Doo Shin; Yong-Sun Kim; Chaeyoung Lee
Journal:  J Hum Genet       Date:  2004-07-22       Impact factor: 3.172

8.  Identification of the cyclin D1b mRNA variant in mouse.

Authors:  Jack Wu; Si-hung Wu; Aliccia Bollig; Archana Thakur; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2008-04-30       Impact factor: 2.316

9.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

10.  Decreased PM10 exposure attenuates age-related lung function decline: genetic variants in p53, p21, and CCND1 modify this effect.

Authors:  Medea Imboden; Joel Schwartz; Christian Schindler; Ivan Curjuric; Wolfgang Berger; Sally L J Liu; Erich W Russi; Ursula Ackermann-Liebrich; Thierry Rochat; Nicole M Probst-Hensch
Journal:  Environ Health Perspect       Date:  2009-05-26       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.